A consortium of investors, including Flagship Pioneering, Amgen, NVentures, Mirae Asset Group, Pictet Alternative Advisors, ADIA, Fidelity Management & Research Company, T. Rowe Price, ARCH Venture, Alaska Permanent Fund, Altitude Life Science Ventures, Morningside Ventures and March Capital, led a $273m Series C round in Generate Biomedicines, a biotechnological company focusing on creating breakthrough medicines. “Our Series C round further propels The Generate Platform to increase significantly the precision, speed, and probability of success of novel therapeutics – positioning us to tackle even more complex targets and unmet patient needs. With our first program now in the clinic and multiple programs expected to enter clinical studies over the next couple of years, we are beginning to realize the enormous potential of generative biology to save and improve the lives of patients in areas where the burden of disease is greatest,” Mike Nally, Generate Biomedicines CEO.